Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 16;23(1):227.
doi: 10.1186/s12964-025-02222-y.

Dynamic changes in macrophage populations and resulting alterations in Prostaglandin E2 sensitivity in mice with diet-induced MASH

Affiliations

Dynamic changes in macrophage populations and resulting alterations in Prostaglandin E2 sensitivity in mice with diet-induced MASH

Madita Vahrenbrink et al. Cell Commun Signal. .

Abstract

Background: The transition from metabolic dysfunction-associated steatotic liver disease (MASLD) to steatohepatitis (MASH) is characterized by a chronic low-grade inflammation, involving activation of resident macrophages (Kupffer cells; KC) and recruitment of infiltrating macrophages. Macrophages produce cytokines and, after induction of Cyclooxygenase 2 (COX-2), the key enzyme of prostanoid synthesis, prostaglandin E2 (PGE2). PGE2 modulates cytokine production in an autocrine and paracrine manner, therefore playing a pivotal role in regulating inflammatory processes. Changes in the hepatic macrophage pool during MASLD progression to MASH could influence PGE2- and cytokine-mediated signaling processes. The aim of this study was to characterize these changes in mice with diet-induced MASH and further elucidate the role of COX-2-dependently formed PGE2 on the inflammatory response in different macrophage populations of mice with a macrophage-specific COX-2-deletion.

Methods: Male, 6-7-week-old wildtype mice were fed either a Standard or high-fat, high-cholesterol MASH-inducing diet for 4, 12 and 20 weeks. Liver macrophages were isolated and analyzed by flow cytometry. For in vitro experiments primary KC, peritoneal macrophages (PM) and Bone-marrow-derived macrophages (BMDM) were isolated from macrophage-specific COX-2-deficient and wildtype mice and treated with lipopolysaccharide (LPS) and/or PGE2.

Results: During MASH-development, the proportion of KC (Clec4F+Tim4+) decreased, while the proportion of monocyte-derived macrophages (Clec4F-Tim4-) and monocyte-derived cells exhibiting a phenotype similar to KC (Clec4F+Tim4-) significantly increased over time. In vitro experiments showed that exogenous PGE2 completely abrogated the LPS-induced mRNA expression and secretion of tumor necrosis factor-alpha (TNF-α) in primary KC, PM and BMDM from wildtype mice. PM and BMDM, as in vitro models for infiltrating macrophages, were more sensitive to PGE2 compared to KC. Deletion of COX-2 in all macrophage populations led to an impaired PGE2-dependent feedback inhibition of TNF-α production. LPSinduced TNF-α mRNA expression was higher compared to the respective wildtype macrophage population.

Conclusion: The current study, using a murine MASH model, indicates that PGE2 may have a protective, anti-inflammatory effect, especially by inhibiting the expression of pro-inflammatory cytokines such as TNFα in infiltrating monocyte-derived macrophages. An inhibition of endogenous PGE2 synthesis in macrophages by pharmacological inhibition of COX-2 could potentially increase inflammation and promote the progression of MASH.

Keywords: Cyclooxygenase; Infiltrating macrophages; Inflammation; Kupffer cells; MASH; Prostaglandin E2; TNF-α.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Dynamic changes in hepatic macrophage populations of mice with diet-induced MASH. (A) Representative density plots of liver macrophage populations at indicated feeding periods. After gating on CD45+, live and singlet cells, macrophages were identified as F4/80+ cells (top panel) and further analysed for expression of Tim4 and Clec4F (bottom panel). (B) Quantification of F4/80+ cells per milligram liver tissue. (C) Proportion of Clec4F+Tim4+ Kupffer cells (KC), Clec4FTim4 monocyte-derived macrophages (MoMF), and Clec4F+Tim4 monocyte-derived Kupffer cells (MoKC) as fractions of F4/80+ cells. Values are median (line), upper- and lower quartile (box) and extremes (whiskers) of n = 4–8 (STD), n = 8–11 (4 W MASH-D), n = 8–13 (12 W MASH-D), n = 9–11 (20 W MASH-D) mice. Statistics: One-way-ANOVA with Tukey´s post hoc test for multiple comparison. *p < 0.05
Fig. 2
Fig. 2
Modulation of TNF-α mRNA and protein expression by exogenous PGE2. Primary Kupffer cells (KC), peritoneal macrophages (PM) and bone marrow-derived macrophages (BMDM) were stimulated for 24 h with LPS and/or PGE2. (A) Relative mRNA expression of TNF-α was determined by RT-qPCR with Hprt as the reference gene. (B) TNF-α protein levels were quantified by ELISA in cell culture supernatants. Values are median (line), upper- and lower quartile (box) and extremes (whiskers) of (A) n = 33 (KC), n = 26 (PM) or n = 29 (BMDM) or (B) n = 27 (KC), n = 26 (PM) or n = 26 (BMDM) independent experiments. Statistics: Two-way-ANOVA with Tukey´s post hoc test for multiple comparison. *p < 0.05
Fig. 3
Fig. 3
PGE2 inhibits TNF-α mRNA and protein expression in a dose-dependent manner. Primary Kupffer cells (KC), peritoneal macrophages (PM) and bone marrow-derived macrophages (BMDM) were stimulated for 24 h with LPS and indicated concentrations of PGE2. (A) Relative mRNA expression of TNF-α was determined by RT-qPCR with Hprt as the reference gene. (B) TNF-α protein levels were determined by ELISA in cell culture supernatants. Values are mean ± SEM of n = 5 independent experiments. Statistics: Student´s t-test for unpaired samples. * vs. w/o PGE2 with p < 0.05
Fig. 4
Fig. 4
Modulation of OSM mRNA expression by exogenous PGE2. Primary Kupffer cells (KC), peritoneal macrophages (PM) and bone marrow-derived macrophages (BMDM) were stimulated for 24 h with LPS and/or PGE2. Relative mRNA expression of OSM was determined by RT-qPCR with Hprt as the reference gene. Values are median (line), upper- and lower quartile (box) and extremes (whiskers) of n = 28 (KC), n = 26 (PM) or n = 30 (BMDM) independent experiments. Statistics: Two-way-ANOVA with Tukey´s post hoc test for multiple comparison. *p < 0.05
Fig. 5
Fig. 5
Modulation of LPS-mediated expression of cyclooxygenase 2 (COX-2) and secretion of prostaglandin E2 (PGE2) in macrophages from wildtype controls (WT) and COX-2-deficient mice (KO). Primary Kupffer cells (KC), peritoneal macrophages (PM) and bone marrow-derived macrophages (BMDM) were stimulated for 24 h with LPS. (A) Relative mRNA expression of COX-2 (gene name Ptges2) was determined by RT-qPCR with Hprt as the reference gene. (B) Protein lysates were analyzed by immunoblotting for COX-2 protein expression, with β-Actin serving as the loading control. All original blots are provided in Supplementary figure S5-7. (C) PGE2 level were determined by ELISA in cell culture supernatants. Values are median (line), upper- and lower quartile (box) and extremes (whiskers) of n = 26–32 (WT) or n = 5–10 (KO) independent experiments. Statistics: Two-way-ANOVA with Tukey´s post hoc test for multiple comparison. *p < 0.05. n.d.: not detectable
Fig. 6
Fig. 6
Modulation of cytokine mRNA and protein expression in macrophages from wildtype controls (WT) and COX-2-deficient mice (KO). Primary Kupffer cells (KC), peritoneal macrophages (PM) and bone marrow-derived macrophages (BMDM) were stimulated for 24 h with LPS. Relative mRNA expression of TNF-α (A) and OSM (C) were determined by RT-qPCR with Hprt as the reference gene. (B) TNF-α protein levels were determined by ELISA in cell culture supernatants. Values are median (line), upper- and lower quartile (box) and extremes (whiskers) of n = 26–32 (WT) or n = 5–10 (KO) independent experiments. Statistics: Two-way-ANOVA with Tukey´s post hoc test for multiple comparison. *p < 0.05

References

    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. 10.1097/HEP.0000000000000520. - PMC - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. 10.1002/hep.28431. - PubMed
    1. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119(9):1787–98. 10.1093/cvr/cvad095. - PMC - PubMed
    1. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. Int J Med. 2010;103(2):71–83. 10.1093/qjmed/hcp158. - PMC - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57. 10.1002/hep.29367. - PubMed

LinkOut - more resources